doc, thanks for posting the transcript. I have trouble

New Post Public Reply Private Reply Replies (0) Message Board
hoops docj #12318
463
doc, thanks for posting the transcript. I have trouble following the CC's and we remember much more than we see than what we hear. Some thoughts:

"Joe, it seems that you think we understand things the way you do. There are shortcuts in your business verbiage that I for one do not understand. It's obvious you know what you are trying to say, but I don't think we get it 100% of the time. This may be one source of the disconnect between some of us shareholders and mgmt. Most of us are not professional traders or in the business community. Maybe you can dummy down some of your comments or organize them in a fashion that will improve our comprehension. It would be appreciated."

Coronavirus:

I'm not sure how much is new in that I don't know if Generex has actually funded any new research for the vaccine. I remember hearing some of the same things during the swine flu epidemic. I don't remember when Ph. I trials were conducted. There certainly haven't been any recent PR's about vaccine research. As Dr. EvH stated how can you test a vaccine once the epidemic is over? It sounds like NGIO recently ramped up the program in response to the CV and are ahead of the field because of its synthetic make-up of the culture.

Nonetheless, there is valid data that can jump start NGIO's efforts. Twenty years of (intermittent) data has to count for something. I'm not sure how meaningful it is that 400 patients tolerated the bird flu vaccine, but it's better than if they got sick from it.

Other than the Shenzhen collaboration with AE 37 and prostate cancer, the entire China angle is a mystery. It takes two to tango as we learned in India. After so many pandemics that started in China maybe they are serious this time and will fund something with NGIO. The potential is excited, but you know what they say about potential-potential gets coaches fired. Joe sounds excited, so I'll share his enthusiasm that something will get done.

" We are now awaiting a contract which we will announce once completed. At this point, we believe we have a deal. That deal will be done once the contract is received and ultimately agreed to. Our upfront payment, just not the work,is received."

Dividends:

They are coming. Only one more week to wait. They'll show up in our accounts on 2/24. It seems clear that much of our progress has been bottle-necked because the dividends couldn't be distributed.

S-1:

Even after reading it, I'm unsure of some of Joe's language. When he say's the S-1 "is up there", I'm not sure what that means. SEC? What is the "addendum of the deal"? Whatever, the S-1 will close after the dividend is paid. "It is our S1 funding, our S1 completion, as well as all the other maintenance Generex needs to do moving forward." I'm not sure what this sentence means, either, and the details of the S-1 funding are still a mystery. Will it serve as a line of credit to be used as needed? How will it be repaid? What are the terms?

NASDAQ Listing:

Still weeks or months away. "We are hoping that over the next weeks to months that all significant assets we have as well as go-forward plans with all subsidiaries. Once the funding comes in, we will be able to just focus on our business model." I don't know what this means.

Whatever it means, I still believe there are PR's stacked up. I don't believe Joe and the mgmt. team have been sitting around waiting for FINRA and the SEC to do their jobs. Uplisting should get the MSO and the other initiatives in the business plan moving forward.

NGIO Spinout:

This should fatten our accounts as well as the GNBT balance sheet. Joe believes it will get Generex over the $2 uplisting requirements. In the Q&A Joe stated that NGIO would be spun out as an IPO.

NGIO itself will be uplisted directly to NASDAQ. The audits have been completed, as is the S-1. Completion of the partner review (I don't know what that is.) should be imminent.

Operations Update:

Funding from the S-1 should enable Generex to sign contracts "with three major clinics in Arizona". Build out of the HMO (I thought it was an MSO.) should follow shortly.

I had enough trouble sorting through mgmt's comments. I'll go through the Q&A later to see if I have any questions or comments of my own. I went through this exercise for my own benefit in order to help me understand where Generex is. Hopefully, it helped others on the board. That's why we're here isn't it?

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 78

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 37

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading

Top 5 Most Recently Viewed Articles

XTransfer Partners with Shanghai Pudong Development Bank for Growth

Updated Category News Views 381

Collaboration on Cross-Border Financial Services XTransfer, recognized as a leading global B2B cross-border trade payment platform, is excited to announce its strategic partnership with Shanghai Pudong Development Bank Co. Ltd., Hong Kong Branch. This collaboration aims to enhance cross-border financial services tailored for SMEs engaged in international trade. Focus on...

Continue Reading
SmartOrderLink: Transforming B2B Order Transactions

Updated Category News Views 29

SmartOrderLink's Role in Streamlining B2B Transactions With every new business platform, there's the promise of smoother operations and less headache, and it seems like transcosmos and Kyoei Sangyo's SmartOrderLink might just cut through the chaos of B2B order transactions. Launched in Tokyo, this online order receipt platform promises to smarten up the process,...

Continue Reading
United Bancshares Sees Strong Start with Q1 2025 Results

Updated Category News Views 121

Financial Performance Overview United Bancshares, Inc. (OTCQX: UBOH) has announced significant financial achievements in early 2025, including a quarterly cash dividend declaration that reflects a solid growth trajectory. Quarterly Dividend and Earnings Highlights The Board has declared a cash dividend of $0.23 per share, marking a notable increase of 4.5%. This dividend,...

Continue Reading
Transforming Contact Center Operations: The Pulse Solution

Updated Category News Views 174

Unlock Business Potential with Pulse by OutboundIQ In the competitive matrix of today’s business landscape, effective decision-making is crucial for sustained growth. OutboundIQ has just become a pivotal player in enabling organizations to harness their data more effectively with the launch of Pulse. This innovative tool is designed specifically for contact centers,...

Continue Reading
Growth of Electronic Materials and Chemicals Market Insights

Updated Category News Views 144

Examining the Rapid Growth of the Electronic Materials and Chemicals Market The Electronic Materials and Chemicals Market is projected to reach an impressive USD 110.2 billion, fueled by consistent growth and a forecasted compound annual growth rate (CAGR) of 6.2% from 2024 to 2032. This increase is largely driven by significant advancements in electronic component...

Continue Reading